Abstract: The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: Described herein are topical formulations of deucravacitinib and methods of making such formulations. Also described are methods of treatment involving the topical administration of such formulations.

Abstract: The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

Abstract: The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

Abstract: A transdermal treatment for erectile dysfunction includes an aqueous solution having a plurality of excipients and a combination of papaverine, phentolamine mesylate and prostaglandin E1.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: A transdermal treatment for erectile dysfunction includes an aqueous solution having a plurality of excipients and a combination of papaverine, phentolamine mesylate and prostaglandin E1.

Abstract: A method for providing mobile messages includes generating a message based on received content. A first functional bind to an aggregator is identified. A second functional bind to the aggregator is also identified. The first functional bind and the second functional bind are distinct communication connections to the aggregator. First message recipients are associated with the first functional bind, and second message recipients are associated with the second functional bind. The message is provided in parallel to the aggregator for the first message recipients through the first functional bind and for the second message recipients through the second functional bind.

Abstract: The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Abstract: A metal shingle having a body with left, right, top and bottom parts. The body is substantially planar and rectangular and has a front, a rear, left and right sides, a top and a bottom. The left and right parts extend from the left and right side respectively. One of the left and right parts is folded over the front and the other is folded over the bottom. The top and bottom parts extend from the top and bottom respectively. One of the top and bottom parts is folded over the front and the other is folded over the bottom. In use, the shingles are positioned in each of side-to-side and top-to-bottom abutting relation so that adjacent sides are interlocked. The body defining a hollow adjacent to one of the interlocking top and bottom parts.

Abstract: A metal shingle having a body with left, right, top and bottom parts. The body is substantially planar and rectangular and has a front, a rear, left and right sides, a top and a bottom. The left and right parts extend from the left and right side respectively. One of the left and right parts is folded over the front and the other is folded over the bottom. The top and bottom parts extend from the top and bottom respectively. One of the top and bottom parts is folded over the front and the other is folded over the bottom. In use, the shingles are positioned in each of side-to-side and top-to-bottom abutting relation so that adjacent sides are interlocked. The body defining a hollow adjacent to one of the interlocking top and bottom parts.

Abstract: The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

Abstract: A metal shingle having a body with left, right, top and bottom parts. The body is substantially planar and rectangular and has a front, a rear, left and right sides, a top and a bottom. The left and right parts extend from the left and right side respectively. One of the left and right parts is folded over the front and the other is folded over the bottom. The top and bottom parts extend from the top and bottom respectively. One of the top and bottom parts is folded over the front and the other is folded over the bottom. In use, the shingles are positioned in each of side-to-side and top-to-bottom abutting relation so that adjacent sides are interlocked. The body defining a hollow adjacent to one of the interlocking top and bottom parts.

Abstract: The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

Abstract: A method for providing mobile messages includes generating a message based on received content. A first functional bind to an aggregator is identified. A second functional bind to the aggregator is also identified. The first functional bind and the second functional bind are distinct communication connections to the aggregator. First message recipients are associated with the first functional bind, and second message recipients are associated with the second functional bind. The message is provided in parallel to the aggregator for the first message recipients through the first functional bind and for the second message recipients through the second functional bind.

Abstract: A transdermal treatment for erectile dysfunction includes an aqueous solution having a plurality of excipients and a combination of papaverine, phentolamine mesylate and prostaglandin E1.

Abstract: A method for providing mobile messages includes generating a message based on received content. A first functional bind to an aggregator is identified. A second functional bind to the aggregator is also identified. The first functional bind and the second functional bind are distinct communication connections to the aggregator. First message recipients are associated with the first functional bind, and second message recipients are associated with the second functional bind. The message is provided in parallel to the aggregator for the first message recipients through the first functional bind and for the second message recipients through the second functional bind.